Human‑derived Oxidized Low‑Density Lipoprotein: A Core Tool for Atherosclerosis Research

A lipoprotein particle "marked" by free radicals quietly replays the critical step leading to arterial plaque formation within human blood vessels in a laboratory dish.

Human Oxidized Low-Density Lipoprotein is a vital reagent repeatedly used in countless cardiovascular disease research laboratories. It mimics the pathological state of the "bad cholesterol" after oxidative modification in vivo, serving as a core molecular tool for uncovering the mechanism of atherosclerosis.

A recent study using cell models established with this reagent screened aptamers that specifically bind Ox-LDL, successfully reducing macrophage uptake by nearly 80%, providing a novel strategy for intervening in plaque formation.

01 Nature and Preparation: What is Human Oxidized Low-Density Lipoprotein?

To understand human Ox-LDL, we start with low-density lipoprotein (LDL), the primary carrier of cholesterol in the bloodstream. LDL consists of a core of cholesteryl esters and triglycerides, surrounded by a surface layer of phospholipids, free cholesterol, and apolipoprotein B100.

In vivo, when LDL is attacked by free radicals, metal ions, and other factors, its lipid components undergo peroxidation, and the protein moiety is modified, transforming it into oxidized low-density lipoprotein.

Compared with native LDL, Ox-LDL undergoes fundamental changes in structure and biological properties. The most significant alteration is the conformational change of its surface apolipoprotein B100, rendering it unrecognizable by the normal LDL receptor.

Instead, it is primarily taken up by scavenger receptors on immune cells such as macrophages. This aberrant metabolic pathway marks the starting point of its pathogenicity.

In the laboratory, human Ox-LDL is mainly prepared by chemical induction. The most classic and widely used method is copper ion-mediated oxidation: purified LDL from healthy human plasma is incubated in a buffer containing trace copper sulfate at 37°C for several hours.

Upon completion of the oxidation reaction, ethylenediaminetetraacetic acid (EDTA) is added to chelate copper ions and terminate the reaction.

To ensure consistency across different batches, strict quality control and characterization are required for the prepared Ox-LDL. Common validation indicators include:

• Thiobarbituric Acid Reactive Substances Assay: Evaluates the content of malondialdehyde, the end product of lipid peroxidation, directly reflecting the oxidation level.
• Agarose Gel Electrophoresis: Ox-LDL exhibits faster electrophoretic mobility than native LDL due to increased negative surface charge.
• Ultraviolet Spectroscopy: Detects the formation of conjugated dienes, an early marker of lipid peroxidation.

Ox-LDL prepared through standardized protocols provides stable and reliable pathological model molecules for research.

02 Pathogenic Core: How Does Ox-LDL Drive Atherosclerosis?

Ox-LDL is regarded as the core bridge connecting dyslipidemia to the inflammatory response in atherosclerosis. Its role in plaque formation is multi-step and cascade-like.

First, Ox-LDL exerts direct injurious and activating effects on vascular endothelial cells. Studies show that treating human umbilical vein endothelial cells with a certain concentration of Ox-LDL significantly reduces cell viability and induces dysfunction.

Damaged endothelium becomes "leaky", facilitating lipid deposition and immune cell infiltration.

The most critical step occurs in the subendothelium. Circulating monocytes migrate here and differentiate into macrophages. Ox-LDL is massively internalized by macrophages via scavenger receptors (e.g., CD36).

Due to the lack of negative feedback regulation of scavenger receptors, the uptake process proceeds uncontrollably, leading to excessive accumulation of cholesteryl esters in macrophages, which transform into "foam cells". Foam cells are the main component of early fatty streaks in atherosclerosis.

In addition to being internalized as a "substrate", Ox-LDL itself is a potent inflammatory and immune activation signal. It stimulates macrophages, endothelial cells, and other cells to release various inflammatory factors, chemokines, and reactive oxygen species, creating a self-reinforcing chronic inflammatory microenvironment that accelerates plaque progression.

Notably, recent research has further refined the pathogenic subtypes of Ox-LDL. Scientists have found that LDL can be divided into five subfractions (L1-L5) based on electrophoretic mobility in the blood of ASCVD patients.

Among them, the L5 subfraction with the fastest mobility and strongest electronegativity has been proven to be the most pathogenic, with atherogenicity far exceeding that of ordinary LDL and even general Ox-LDL preparations. This suggests that future research may require more refined models.

To clarify the essential differences between Ox-LDL and native LDL, the table below compares multiple dimensions:

03 Application Scenarios: Where Does Ox-LDL Excel in Experiments?

As a "star molecule" in cardiovascular research, especially in the field of atherosclerosis, Ox-LDL is widely used in various in vitro and in vivo models to simulate different stages and aspects of the disease.

In Vitro Cell Models

Foam Cell Formation Model: This is the most classic and direct application. Co-culture macrophages (e.g., RAW 264.7 cells, THP-1-derived macrophages, or mouse bone marrow-derived macrophages) with different concentrations of Ox-LDL.

Intracellular lipid droplet formation is observed by Oil Red O staining, or total cholesterol/cholesteryl ester content is measured to quantify foam cell formation, enabling screening of drugs or molecules with potential anti-atherosclerotic effects.

Vascular Endothelial Cell Injury Model: Stimulate vascular endothelial cells such as human umbilical vein endothelial cells with Ox-LDL. Endothelial dysfunction and drug protective effects are evaluated by measuring cell viability, apoptosis rate, reactive oxygen species levels, expression of adhesion molecules (e.g., VCAM-1, ICAM-1), and monocyte adhesion capacity.

Autophagy and Metabolism Research: Abnormal accumulation of Ox-LDL interferes with the normal autophagy-lysosomal degradation pathway. Studies detect the expression of autophagy marker proteins LC3-II and p62 via Western Blot to explore how Ox-LDL affects lipophagy and how protective factors (e.g., Humanin peptide) promote Ox-LDL clearance by restoring autophagic flux.

Molecular Mechanism Research

Receptor and Signaling Pathway Research: Fluorescently labeled Ox-LDL (e.g., Dil-OxLDL) is used to directly visualize and quantify Ox-LDL uptake by macrophages via flow cytometry or fluorescence microscopy.

Combined with specific antibodies or inhibitors, the role of scavenger receptors such as CD36 and downstream signaling pathways (e.g., inflammasome activation, apoptosis) can be thoroughly investigated.

Antibody and Detection Technology Development: As a key disease biomarker, Ox-LDL is used as an immunogen to develop monoclonal antibodies targeting specific epitopes. These antibodies are used to establish highly sensitive and specific sandwich ELISA assays for quantitative analysis of Ox-LDL levels in clinical samples to assess cardiovascular disease risk.

In Vivo Animal Models

In atherosclerotic model animals such as ApoE-deficient or LDL receptor-deficient mice, exogenous Ox-LDL is rarely directly injected. However, when analyzing lipoproteins isolated from serum or lesion sites of model animals, Ox-LDL or its specific antibodies (e.g., anti-Ox-LDL antibodies) are important indicators for evaluating plaque oxidative stress levels and lesion severity.

04 Challenges and Future: Refined Models and Translational Applications

Although Ox-LDL has become an indispensable research tool, the field still faces challenges and continues to advance. Ox-LDL produced by the current standardized copper ion oxidation method is a heterogeneous mixture, whose oxidation degree and specific modification sites may not fully replicate Ox-LDL generated in the complex in vivo microenvironment.

As mentioned earlier, specific pathogenic subfractions such as L5 with strong electronegativity may exhibit stronger biological activity than ordinary Ox-LDL. Developing Ox-LDL subtype preparations that more accurately simulate different disease stages or specific pathological modifications will be a future direction.

On the other hand, the ultimate goal of research is clinical translation. Based on in-depth understanding of Ox-LDL pathogenic mechanisms, novel therapeutic strategies are being explored. For example, recent studies screened aptamers that bind to specific regions of ApoB100 on Ox-LDL, successfully "coating" Ox-LDL and blocking its recognition by macrophages, providing proof-of-concept for developing targeted therapeutic drugs.

Meanwhile, developing stable and reliable clinical detection methods for Ox-LDL as a novel biomarker for predicting cardiovascular events and evaluating plaque stability has broad clinical application prospects.

As scientists observe foam cells engorged by Ox-LDL under the microscope, the pathological drama within blood vessels is being decoded. From elucidating basic mechanisms to incubating innovative therapies and diagnostic tools, this seemingly simple reagent acts as a key to unlocking the mysteries of cardiovascular disease.

Recommended Absin Human Oxidized Low-Density Lipoprotein:

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio